Dronedarone: 6 agencies, 2009–2012
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
Where dronedarone met resistance it was usually narrowed rather than refused: 2 of 5 decisive outcomes were recommendations with restrictions, against 1 outright refusal.
The record spans 3.2 years, opening at AWMSG (Wales) on 11 May 2009 and running to 2 Aug 2012.
HAS (France) changed its position: recommended on 2 Jun 2010, not recommended by 22 Jun 2011.
No assessment is on file from PBAC (Australia), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Nothing has been added since 2012; on this evidence the file is dormant.
3 distinct indication wordings are recorded for dronedarone by the agencies that label one in English (AWMSG, NICE and SMC).
AWMSG (Wales) was first to assess dronedarone, on 11 May 2009; PHARMAC (New Zealand) did not open a file until 2 Aug 2012 — a wide spread of 3.2 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 4 of 7 dated records fall in 2010 alone.
Restriction is doing real work here: 2 of 5 decisive outcomes narrowed dronedarone to a subgroup rather than accepting or refusing it outright, at SMC (Scotland) and TLV (Sweden).
HAS (France) is the only agency to have returned to dronedarone, recording 2 separate entries.
6 of the 18 agencies in this archive hold a record for dronedarone.
The full ledger for dronedarone reads 2 restricted, 2 recommended, 1 deferred and 1 not recommended, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PHARMAC (New Zealand) | 2 Aug 2012 | Atrial fibrillation | PTAC advice: Deferred · decision reached | source |
| HAS (France) | 22 Jun 2011 | Re-assessment of SMR and ASMR | SMR insufficient | source |
| SMC (Scotland) | 13 Sep 2010 | For the treatment of atrial fibrillation | accepted (restricted) | source |
| NICE (England) | 25 Aug 2010 | NICE TA197 | recommended | source |
| TLV (Sweden) | 20 May 2010 | Multaq ingår i högkostnadsskyddet med begränsning | restricted subsidy | source |
2 further decisions for dronedarone, across 2 agencies, are not shown here. They link to 1 further source document.
Related molecules
- lidocaine — same ATC class C01B — Cardiac therapy
- mexiletine — same ATC class C01B — Cardiac therapy
- lidocaine / prilocaine — same ATC class C01B — Cardiac therapy
- cefuroxime — also decided by PHARMAC in 2012Q3
- mupirocin — also decided by PHARMAC in 2012Q3
- erythromycin — also decided by PHARMAC in 2012Q3
Coverage: 7 decisions for dronedarone from 6 agencies, 2009 to 2012. Data to 7 Sep 2026. ATC class C01B — Cardiac therapy. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.